New €25 Million BioReliance Testing Facility Opens at Merck KGaA Global Headquarters in Germany

Positive

AI Analysis

Summary

Merck KGaA opened a new €25 million BioReliance testing facility in Darmstadt, Germany, offering GMP-compliant stability studies for monoclonal antibodies and cell therapies to address growing biologics testing demand in Europe.

Importance:3/10

Sentiment:

0.60

infrastructuretesting facilitybiologicsmonoclonal antibodiescell therapiesGMP-compliantEurope

Related Companies

$MKKGY

Read the original article

Published by GEN - Genetic Engineering & Biotech News on July 20, 2026 12:00 PM

Read Original